Urgent-Start Peritoneal Dialysis as a Feasible Alternative Therapy for End-Stage Renal Disease Patients

随着终末期肾病(ESRD)全球患病率的持续上升，部分患者因病情进展迅速或延迟转诊而需紧急透析治疗。传统上，中心静脉置管(CVC)血液透析(HD)是紧急起始透析的主要方式，但其导管相关感染、血栓形成等并发症风险较高，且医疗成本昂贵。近年来，紧急起始腹膜透析(USPD)作为一种替代方案逐渐受到关注。多项研究表明，USPD在安全性、疗效及卫生经济学方面具有显著优势，其临床结局与传统计划性PD及紧急起始HD相当，同时能降低感染风险、减少侵入性操作并优化医疗资源利用。本文综述USPD的临床应用进展，探讨其在ESRD紧急透析治疗中的价值及前景。With the continuous rise in the global prevalence of end-stage renal disease (ESRD), some patients require urgent dialysis due to rapid disease progression or delayed referral. Traditionally, hemodialysis (HD) via central venous catheter (CVC) has been the primary method for urgent-start dialysis. However, it carries a high risk of catheter-related infections, thrombosis, and other complications, along with substantial medical costs. In recent years, urgent-start peritoneal dialysis (USPD) has emerged as an alternative approach. Numerous studies indicate that USPD offers significant advantages in terms of safety, efficacy, and cost-effectiveness, with clinical outcomes comparable to those of conventional planned PD and urgent-start HD. Additionally, USPD reduces infection risks, minimizes invasive procedures, and optimizes healthcare resource utilization. This article reviews the clinical advancements of USPD and explores its value and prospects in the emergency management of ESRD.